{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:04:31Z","timestamp":1790744671895,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":6065,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1111\/j.1538-7836.2006.01882.x","type":"journal-article","created":{"date-parts":[[2006,4,7]],"date-time":"2006-04-07T06:19:40Z","timestamp":1144390780000},"page":"1029-1036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":112,"title":["Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease"],"prefix":"10.1016","volume":"4","author":[{"given":"A.","family":"UNDAS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"CELINSKA\u2010L\u00d6WENHOFF","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"L\u00d6WENHOFF","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"SZCZEKLIK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1749-6632.2001.tb03491.x","article-title":"The structure and biological features of fibrinogen and fibrin","volume":"936","author":"Mosesson","year":"2001","journal-title":"Ann NY Acad Sci"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0049-3848(94)90227-5","article-title":"Fibrin in human plasma: gel architecture governed by rate and nature of fibrinogen activation","volume":"5","author":"Blomb\u00e4ck","year":"1994","journal-title":"Thromb Res"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0020","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1055\/s-0038-1650618","article-title":"Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age","volume":"76","author":"Fatah","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1055\/s-0038-1656337","article-title":"Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis","volume":"68","author":"Fatah","year":"1992","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0030","doi-asserted-by":"crossref","first-page":"21331","DOI":"10.1074\/jbc.M212734200","article-title":"Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin\u2010rich clots","volume":"278","author":"Collet","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0035","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1161\/01.ATV.0000136649.83297.bf","article-title":"Genetic and environmental determinants of fibrin structure and function. Relevance to clinical disease","volume":"24","author":"Scott","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0040","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1053\/euhj.1998.1088","article-title":"Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid","volume":"19","author":"Williams","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00001721-200501000-00010","article-title":"Modifications of flow measurements to determine fibrin gel permeability and the preliminary use in research and clinical materials","volume":"16","author":"He","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0050","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/archinte.163.10.1155","article-title":"Renin\u2010angiotensin system and atherothrombotic disease","volume":"163","author":"Jacoby","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0055","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1161\/01.CIR.0000139312.10076.BA","article-title":"Update on statins: 2003","volume":"110","author":"Vaughan","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0060","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00041433-200312000-00005","article-title":"Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy","volume":"14","author":"Robins","year":"2003","journal-title":"Curr Opin Lipidol"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0065","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1160\/TH04-02-0064","article-title":"New nonlipid effects of statins and their clinical relevance in cardiovascular disease","volume":"91","author":"Undas","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0070","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/01.HYP.34.4.987","article-title":"Statins and blockers of the renin\u2010angiotensin system. Vascular protection beyond their primary mode of action","volume":"34","author":"Faggiotto","year":"1999","journal-title":"Hypertension"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(03)00156-4","article-title":"Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives","volume":"171","author":"Chapman","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0080","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1161\/01.CIR.0000033221.73082.06","article-title":"Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease","volume":"106","author":"Mills","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0085","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/00001721-199512000-00004","article-title":"The effect of acetyl salicylic acid on fibrin gel lysis by tissue plasminogen activator","volume":"6","author":"Williams","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0090","doi-asserted-by":"crossref","first-page":"16948","DOI":"10.1016\/S0021-9258(17)44852-6","article-title":"The activated protein C\u2010mediated enhancement of tissue\u2010type plasminogen activator\u2010induced fibrinolysis in a cell\u2010free system","volume":"265","author":"Bajzar","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0095","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1055\/s-0037-1614859","article-title":"Abnormal fibrin clot architecture in nephritic patients is related to hypofibrinolysis: influence of plasma biochemical modifications","volume":"82","author":"Collet","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0100","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-0037-1615701","article-title":"Treatment with simvastatin and low dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline high cholesterol levels","volume":"85","author":"Musial","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0105","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1161\/01.CIR.103.18.2248","article-title":"Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation","volume":"103","author":"Undas","year":"2001","journal-title":"Circulation"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0110","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood.V98.8.2423","article-title":"Blood coagulation at the site of microvascular injury: effects of low\u2010dose aspirin","volume":"98","author":"Undas","year":"2001","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0115","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1182\/blood.V96.7.2479.h8002479_2479_2486","article-title":"Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia","volume":"96","author":"Balogh","year":"2000","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0120","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0021-9150(01)00552-4","article-title":"A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration","volume":"160","author":"Maison","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0125","doi-asserted-by":"crossref","first-page":"12H","DOI":"10.1016\/S0002-9149(03)00429-6","article-title":"Role of 3\u2010hydroxy\u20103\u2010methylglutaryl coenzyme A reductase inhibitors, angiotensin\u2010converting enzyme inhibitors, cyclooxygenase\u20102 inhibitors, and aspirin in anti\u2010inflammatory and immunomodulatory treatment of cardiovascular disease","volume":"91","author":"Schieffer","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0130","doi-asserted-by":"crossref","first-page":"670","DOI":"10.7326\/0003-4819-139-8-200310210-00011","article-title":"Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review","volume":"139","author":"Balk","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0135","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2165\/00003495-200363170-00005","article-title":"Effects of HMG\u2010CoA reductase inhibitors on coagulation and fibrinolysis processes","volume":"63","author":"Krysiak","year":"2003","journal-title":"Drugs"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0140","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2002-08-2527","article-title":"Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk","volume":"101","author":"Wolberg","year":"2003","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0145","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1161\/01.HYP.34.2.285","article-title":"Comparative effect of angiotensin\u2010converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans","volume":"34","author":"Brown","year":"1999","journal-title":"Hypertension."},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0150","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/BF00315549","article-title":"Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction","volume":"44","author":"Jansson","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0155","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0895-7061(97)00496-2","article-title":"Antihypertensive drug treatment and fibrinolytic function","volume":"11","author":"Lottermoser","year":"1998","journal-title":"Am J Hypertens"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0160","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1182\/blood.V100.3.743","article-title":"Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms","volume":"100","author":"Ari\u00ebns","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1538-7836.2006.01882.x_bb0165","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1749-6632.2001.tb03514.x","article-title":"Inhibition of fibrinolysis by lipoprotein(a)","volume":"936","author":"Angles\u2010Cano","year":"2001","journal-title":"Ann N Y Acad Sci"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1538-7836.2006.01882.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622122270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622122270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1538-7836.2006.01882.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:37:37Z","timestamp":1761532657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622122270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S1538783622122270"],"URL":"https:\/\/doi.org\/10.1111\/j.1538-7836.2006.01882.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1538-7836.2006.01882.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}